About Greg

Greg Perry joined the Medicines Patent Pool (MPP) as Executive Director in January 2013, bringing more than 20 years of experience in pharmaceuticals, intellectual property and healthcare policy to the foundation. Prior to his role at the MPP, he served as Founding Director and later Director General of the European Generic Medicines Association. He also was a founding member of the International Generic Pharmaceutical Alliance. Previously he worked as a European Union policy advisor to corporate as well as non-governmental organisations and prior to that as parliamentary advisor to Members of the European Parliament. In 2004, he was awarded the Golden Cross of Merit of the Republic of Poland for his contribution to industry and European integration, one of a few non-Polish nationals to be honoured with this distinction. Perry was a member of the Standing Advisory Committee before the European Patent Office (SACEPO) for five years and is currently an Honorary Life Fellow of the Organisation for Professionals in Regulatory Affairs in the United Kingdom (TOPRA) UK. Under his direction, the MPP launched new licensing agreements to improve access to HIV, hepatitis C and tuberculosis treatments in developing countries.

This speaker will be presenting at the following session(s)

  • Speeding access to innovative hepatitis C products: Unitaid’s key role


    Day: 1 November

    Time: 17:30

    This evening side meeting presents Unitaid’s investment and operating model in the context of the emerging global response to hepatitis C. It will share the results of Unitaid-funded projects related to hepatitis C. It will also explore opportunities for potential future investments. 


    • Opening remarks – Unitaid’s model and its relevance for Hepatitis C.
    • Where are we today?
    • Developing a simplified mode of care for HCV.
      Anne Loarec, Médicins Sans Frontère
    • Creating demand and innovative solutions for access to HCV treatment.
      Khalil Elouardighi, Coalition Plus
    • Facilitating access to HCV treatment through voluntary licensing
      Greg Perry, Medicines Patent Pool
    • Facilitating diagnostic solutions
      Francesco Marinucci, FIND
    • Putting the pieces together to maximise benefits.
      Dr. Marc Bulterys, World Health Organization
    • Moderated discussion.
  • Options for countries with access to generic hepatitis medicines

    Ballroom 2

    Day: 2 November

    Time: 12:00

    Chair: Dr. Jean Damascène Makuza, Rwanda Biomedical Center and Tracy Swan, Médecins Sans Frontières


    • Country example: Rwanda.
      Dr. Jean Damascène Makuza, Rwanda Biomedical Center
    • The impact of generics in scaling up treatment.
    • Dr. Saeed Hamid, The Aga Khan University, Pakistan
    • Voluntary licensing.
      Greg Perry, Medicines Patent Pool
    • Basics of access to medicines for hepatitis programme managers.
    • Madisyn Lu, Clinton Health Access Initiative
    • Q & A session.